

References

- Adams, D.D. and Purves, H.D.(1956):** Abnormal responses in the assay of thyrotropins. Proc Univ Otago Sch Med 34:11–12.
- Akbar, A. N.; Taams, L. S. and Salmon, M. (2003):** The peripheral generation of CD4⁺ CD25⁺ regulatory T cells. Immunology; 109: 31925.
- Albert, M. L.; Kim, J. I. and Birge, R. B. (2000):** Dendritic Cells Cross-Present Apoptotic Cells Nature Cell Biol. 2, 899.
- Al-Kaabi , J.M.; Hussein, S. S. and Bukheit ,C.S. (2002):** Radioactive iodine in the treatment of Graves'' disease. Saudi Med J. 23:1049-53.
- Allahabadia, A.; Daykin, J.; Sheppard, M.C.; Gough, S.C. and Franklyn, J.A. (2001):** Radioiodine Treatment of Hyperthyroidism—Prognostic Factors for Outcome The Journal of Clinical Endocrinology & Metabolism 86(8): 3611-17.
- Almeida, A. R.; Legrand, N .; Papiernik, M. and. Freitas, A. A. (2002):** Homeostasis of peripheral CD4⁺ T cells: IL-2R α and IL-2 shape a population of regulatory cells that controls CD4⁺ T cell numbers. J. Immunol. 164:4850-60.
- Alsanea, O. and Clark, O. H. (2000):** Treatment of Graves'' disease: the advantages of surgery. Endocrinol Metab Clin North Am 29:321-37.

- Ando, T.; Imaizumi, M.; Graves, P.N.; Unger, P. and Davies, T.F. (2002):** Intrathyroidal fetal microchimerism in Graves' disease. *J Clin Endocrinol Metab* 87:3315-20.
- Andrew, D. and Aspinall, R. (2001):** IL-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. *J Immunol.* **166**:1524–30.
- Aust, G.; Lehmann, I. and Heberling, H. J. (1996):** Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease. *Exp Clin Endocrinol Diabetes* 104(1):50-8.
- Bach, J.F. (2002):** The effect of infections on susceptibility to autoimmune and allergic diseases. *N Engl J Med* 347:911-20.
- Bahn, R.S. and Heufelder, A.E. (1993):** Mechanisms of disease: pathogenesis of Graves' ophthalmopathy. *N Engl J Med* 329: 1468-75.
- Barclay, M. L.; Brownlie, B. E.; Turner, J. G. and Wells, J. E. (1994):** Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. *Clin Endocrinol (Oxf)*;40:759-64.
- Bartalena, L.; Bogazzi, F.; Tanda, M.L.; Manetti. L.; Dell'Unto, E. and Martino, E.(1995):** Cigarette smoking and the thyroid. *Eur J Endocrinol*;133:507-12.
- Bartalena, L.; Tanda, M. L. and Piantanida, E. (2004):** Relationship between management of hyperthyroidism and course of the ophthalmopathy. *J Endocrinol Invest*; 27: 288-94.
- Bednarczuk, T.; Hiromatsu, Y.; Fukutani, T.; Jazdzewski, K.; Miskiewicz, P.; Osikowska, M. and Nauman, J.(2003):** Association of cytotoxic T-

lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. *Eur J Endocrinol* 148:13–18.

Beissert, S .; Schwarz, A. and Schwarz, T. (2006): Regulatory T Cells *Journal of Investigative Dermatology* **126**, 15–24.

Belkaid, Y.; Piccirillo, C.A.; Mendez, S.; Shevach, E.M. and Sacks, D.L.(2002): CD4+CD25+ regulatory T cells control *Leishmania* major persistence and immunity . *Nature* **420** (6 9 1 5) : 5 0 2 - 7 .

Bellur, S. P.; Rebecca, S. B. and Terry, J. S.(2003): Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy *Endocrine Reviews* **24** (6) : 802-35 .

Bluestone, J.A and Abbas, A. K.(2003): Natural versus adaptive regulatory T cells. *Nat Rev Immunol*; **3**: 2537.

Bluestone, J.A. (2005): Regulatory T-cell therapy. is it ready for the clinic? *Nat Rev Immunol*. **5**:343–9.

Bossowski, A.; Urban, M. and Stasiak-Barmuta, A. (2003): Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, subsets CD4, CD8 and their memory (CD45RO), and naive (CD45RA) T cells in children with immune and non-immune thyroid diseases. *J Pediatr Endocrinol Metab* **16**(1):63-70.

Boyum, A.(1968): Lymphocyte separation. *Scan J Clin. Invest.* **21** : 7.

Brabant, G.; Bergmann, P.; Kirsch, C.M.; Köhrie, J.; Hesch, R.D. and von zur Mühlen, A. (1992): Early adaptation of thyrotropin and thyroglobulin

secretion to experimentally decreased iodine supply in man. *Metabolism*; 41:1093-6.

Braford, D.; Flint, A.J. and Tonks, N.K.(1994): Crystal structure of human phosphatase 1B.. *Science* 11:253(5152):1373.

Brix, T. H.; Kyvik, K.O.; Christensen, K. and Hegedus, L.(2001): Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. *J Clin Endocrinol Metab* 86:930–34

Brown, R.S.; Bellisario, R.L.; Botero, D.; Fournier, L.; Abrams, C.A.; Cowger, M.L.; David, R.; Fort, P. and Richman, R.A.(1996): Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies. *J Clin Endocrinol Metab.*; 81:1147-51.

Burek, C. L. and Rose, N.R. (1995): Autoantibodies. In: Colvin, R.B.; Bhan, A. K. and McCluskey, R.T. ed. *Diagnostic Immunopathology*, 2nd ed.. New York: Raven Press: 207-30.

Burman, K.D.; Lukes, Y.G. and Gemiski, P.(1991): Molecular homology between the human TSH receptor and *Yersinia enterocolitica*. *Thyroid* 1(Suppl 1):S62.

Burnet, F. M. (1959): The Clonal Selection Theory of Acquired Immunity. *Australian Journal of Science* **20**, 67-9.

Cao, D.; Vollenhoven, R.; Klareskog, R.; Trollmo, C. and Malmström, V. (2004): CD25^{bright}CD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. *Arthritis Res Ther.* 6(4): 335–46.

- Cao, Q.; Wang, L.; Du, F.; Sheng, H.; Zhang, Y.; Wu, J.; Shen, B.; Shen, T.; Zhang, T.; Li, D. and Li, N. (2007):** Downregulation of CD4⁺CD25⁺ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. *Cell Research*. 17:627–37.
- Carreno, B.M. and Collins, M. (2002):** The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. *Annu Rev Immunol*; 20: 29–53
- Carrier, C.; Yuan, J.; Kuchroo, V. and Weiner, H. (2007):** Th3 Cells in Peripheral Tolerance. Induction of Foxp3-Positive Regulatory T Cells by Th3 Cells Derived from TGF- β T Cell-Transgenic Mice. *The Journal of Immunology*, 178: 179-85.
- Cavallaro, J. J. Palmer, D. F and Bigazzi, P. E. (1976):** Immunofluorescence detection of autoimmune diseases. *Immunology series No.7*. Centers for Disease Control.
- Cawood, T.; Moriarty, P. and O'Shea, D. (2004):** Recent developments in thyroid eye disease. *BMJ*. 329:385-90.
- Cederbom, L.; Hall, H. and Ivars, F. (2000):** CD4⁺ CD25⁺ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. *Eur J Immunol*; 30: 1538-43.
- Chen, Q.Y.; Huang, W.; She, J.X.; Baxter, F.; Volpe, R. and MacLaren, N.K. (1999):** HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American

Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 84:3182-86.

Chen, W.; Jin, W.; Hardegen, N.; Lei, K. J.; Li, L.; Marinos, N.; McGrady, G. and Wahl, S.M. (2003): Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. **198**:1875–86.

Chen, Y.; Shi, H.; Qin, X.; Mo, W.; Liang, X.; Huang, Z.; Yang, H. and Wu, C.(2005): CD4⁺CD25⁺ Regulatory T Lymphocytes in Malignant Pleural Effusion Am. J. Respir. Crit. Care Med., 172: 11- 1434-39.

Chen, W.; Diao, J.; Stepkowski, S. M. and Zhang, L. (2007): Both Infiltrating Regulatory T Cells and Insufficient Antigen Presentation Are Involved in Long-Term Cardiac Xenograft Survival. J. Immunol. 179: 1542-48.

Cheng, E.H.; Sheiko, T. V.; Fisher, J. K.; Craigen, W. J. and Korsmeyer, S. J. (2003): mitochondrial apoptosis. Science. 25;301(5632):513-7.

Chiovato, L. and Pinchera, L.(1996): Stressful life events and Graves' disease. Eur J Endocrinol;134:680-82.

Coles, A. J.; Wing, M. G. and Smith, S. (1999): Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet; 354:1691-95.

- Cooper, D. S. (2005):** Antithyroid Drugs. NEJM 352: 905-17.
- Cottrez, F. and Groux H.(2004):** Specialization in tolerance: innate CD(4+) CD(25+) versus acquired TR1 and TH3 regulatory T cells. Transplantation. 77(1): 12–15.
- Cruz, A. A.; Akaishi, P. M.; Vargas, M. A. and de Paula, S. A. (2007):** Association Between Thyroid Autoimmune Dysfunction and Non-Thyroid Autoimmune Diseases. Ophthalmic Plastic & Reconstructive Surgery. 23(2):104-8.
- Czarnocka, B.; Ruf, J.; Ferrand, M.; Carayon, P. and Lissitzky, S. (1985):** Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid diseases. FEBS Lett. 190(1):147–52.
- Dang, S. and Shi, B.(2006):** Variance of CD4+CD25+T Regulatory Cells in Graves Disease. HKMJ. 12 (6): 78.
- Danial, N. N. and Korsmeyer, S. J. (2004):** "Cell Death: Critical Control Points". Cell. 116: 205-19.
- Daniel R. G.(2004):** Toll Like receptors and other links between innate and acquired alloimmunity. Current Opinions in Immunology, (16): 534-44.
- De Maria, R. and Testi, R.(1998) :** Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol Today 19:121-25.

- DeGroot, L.J and Quintans, J. (1989):** The causes of autoimmune thyroid disease. *Endocrine Rev* 10:537-62.
- Dejaco, C.; Duftner, C.; Grubeck-Loebenstien, B. and Schirmer M. (2006):** Imbalance of regulatory T cells in human autoimmune diseases . *Immunology*. 117(3): 289–300.
- Di Cerbo, A.; Di Paola, R.; Menzaghi, C.; De Filippis, V.; Tahara, K. and Corda, D. (1999):** Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on the thyrotropin receptor. *J Clin Endocrinol Metab*;84:3283-92.
- Dieckmann, D.; Bruett, C. H.; Ploettner, H.; Lutz, M. B. and Schuler, G. (2002).** Human CD4(+)CD25(+) Regulatory, Contact-dependent T Cells Induce Interleukin 10-producing, Contact-independent Type 1-like Regulatory T Cells. *J Exp Med*, 196, 247-53.
- Dillman, W.H. (1997):** Thyroid storm. *Curr Ther Endocrinol Metab* 6:81-85.
- Donner, H.; Rau, H.; Walfish, P. G.; Braun, J.; Siegmund, T.; Finke, R.; Herwig, J.; Usadel, K.H. and Badenhoop, K. (1997):** CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. *J Clin Endocrinol Metab* 82:143–46.
- Durelli, L.; Ferrero, B.; Oggero, A.; Verdun, E.; Ghezzi, A.; Montanari, E. and Zaffaroni, M.(2001):** Thyroid function and autoimmunity during Interferon β -1b treatment: A multicenter prospective study. *J Clin Endocrinol Metab* 86:3525-32.

- Eales, J.G. (1988):** The influence of nutritional state on thyroid function in various vertebrates. *Amer Zool*; 28:351-62.
- Erickson, L.A.; Yousef, O.M.; Jin ,L.; Lohse, C.M.; Pankratz,V.S. and Lloyd, R.V.(2002):** Presence of birefringent crystals is useful in distinguishing thyroid from parathyroid gland tissues. *Am J Surg Pathol.*;26(6):813-4.
- Feldon, S.E.; John Park, D. J.; O'Loughlin, C.W.; Nguyen, V. T.; Landskroner, S.; Chang, D.; Thatcher, T.H. and Phipps R.P. (2005):** Autologous T-Lymphocytes Stimulate Proliferation of Orbital Fibroblasts Derived from Patients with Graves' Ophthalmopathy. *Investigative Ophthalmology and Visual science* .46 : 3913- 21 .
- Feldt-Rasmussen, U.; Schleusener, H. and Carayon, P. (1994):** Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. *J Clin Endocrinol Metab* : 78 : 98 – 103 .
- Ferry, M.; Jones, D. J.; Vaux, I. S. ; Roberts, D. and Cornall, R. J. (2003):** The Cellular Location of Self-antigen Determines the Positive and Negative Selection of Autoreactive B Cells. *J. Exp. Med.* **198**, 1415-25.
- Fisfalen, M.E.; Palmer, E.M.; Van Seventer, G.A.; Soltani, K.; Sawai, Y.; Kaplan, E.; Hidaka, Y.; Ober, C. and De Groot, L.J. (1997):** Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. *Journal of Clinical Endocrinology and Metabolism*, **82**, 3655–63.

- Fontanilla ,J. C.; Schneider, A.B. and Sarne, D.H. (2001):** The use of oral radiographic contrast agents in the management of hyperthyroidism. *Thyroid* 11:561–67.
- Fontenot, J.D.; Gavin, M.A. and Rudensky, A.Y. (2003):** Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. *Nat Immunol* 4:330–36.
- Foussat, A.; Cottrez, F.; Brun, V .; Fournier, N.; Breitmayer, J. and Groux, H.(2003):** A Comparative Study between T Regulatory Type 1 and CD4⁺CD25⁺ T Cells in the Control of Inflammation *The Journal of Immunology*, 171: 5018-26.
- Fukutani, T.; Hiromatsu, Y.; Kaku, H.; Miyake, I.; Mukai, T.; Imamura, Y.; Kohno, S.; Takane, N.; Ahoji, S.; Otabe, S. and Yamada, K. (2004):** A polymorphism of interferon γ gene associated with changes of anti-TSH receptor antibodies induced by anti-thyroid drug treatment for Graves' disease in Japanese. *Thyroid* 14:93–97.
- Furtado, G. C.; Curotto, M.A. and Kutchukhidze N. (2002):** Interleukin 2 signaling is required for CD4(+) regulatory T cell function. *J Exp Med.*;196:851–57.
- Georgala, S.; Katoulis, A.C. and Georgala, C. (2002):** Pretibial myxedema as the initial manifestation of Graves' disease. *J Eur Acad Dermatol Venereol.* 16:380–3.
- Gilquin, J.; Viard, J.P.; Jubault, V.; Sert, C. and Kazatchkine, M.D. (1998):** Delayed occurrence of Graves' disease after immune restoration with HAART: highly active antiretroviral therapy. *Lancet*;352:1907-8.

- Ginsberg, J. (2003):** Diagnosis and management of Graves' disease. CMAJ 168(5).
- Givan, A.(2001):** Flow Cytometry: First Principles. New York: Wiley-Liss. 273p.
- Goyal, P.; Kale, S.C.; Chaudhry, R.; Chauhan, S. and Shah, N.(2007):** Association of common chronic infections with coronary artery disease in patients without any conventional risk factors. Indian J Med Res; 125 : 129-36.
- Graca, L.; Chen, T. C.; Le Moine, A.; Cobbold, S.P.; Howie, D. and Waldmann, H. (2005):** Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. Trends Immunol. 26:130–5.
- Grossman, W.J.; Verbsky, J. W. and Barchet, W.(2004):** Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 21:589–601.
- Groux, H.; O'Garra, A.; Bigler, M.; Rouleau, M.; Antonenko, S.; de Vries, J.E. and Roncarolo, M.G. (1997):** A CD4⁺ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature **389**, 737-24.
- Grumet ,F.C.; Payne, R.O.; Konishi, J. and Kriss, J.P. (1974):** HLA antigens as markers for disease susceptibility and autoimmunity in Graves' disease. J Clin Endocrinol Metab 39:1115–19.
- Gupta, M.K. (2000):** Thyrotropin-receptor antibodies in thyroid diseases: advances in detection techniques and clinical application. Clin Chem Acta;293:1-29.
- Hamada, N.; DeGroot, L.J.; Portmann, L.; Yamakawa, J.; Noh, J.; Okamoto, Y.; Ohno, M.; Ito, K. and Morii, H. (1991):** Thyroid microsomal antigen in Graves' thyroid is not different from that in normal thyroid. Endocrinol Japan 38:471-78.

- Han, R. and Smith, T. J. (2006):** T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-1{beta} in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy. *Endocrinology*. 147(1): 13 - 19.
- Harper, M. B. and Mayeaux, E. J. (2003):** Thyroid disease. In: Taylor RB. *Family medicine: principles and practice*. 6th ed. New York: Springer, 1042-52.
- Hauben, E and Grazia ,M.(2005):** Human CD4+ regulatory T cells and activation-induced tolerance .*Microbes and Infection* .Volume 7, Issues 7-8, 1023-32.
- Heuer, M.; Aust, G.; Ode-Haim, S. and Scherbaum, W.A. (1996):** Different cytokine mRNA profile in Graves' disease, Hashimoto's thyroiditis, and non autoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). *Thyroid*, **6**, 97–105.
- Heyman, P.; Harrison, L. C.; Robins, B. R.(1986):** Thyrotropin (TSH) binding sites on *Yersinia enterocolitica* recognized by immunoglobulins from humans with Graves' disease. *Clin Exp Immunol* 64:249–54
- Hidaka, Y.; Kimura, M.; Izumi, Y.; Takano, T.; Tatsuyo, O. and Amino, N.(2003):** Increased serum concentration of eosinophil-derived neurotoxin in patients with Graves' disease. *Thyroid* 13: 129-32.
- Hiratani, H., Bowden, D.W.; Ikegami, S.; Shirasawa, S.; Shimizu, A.; Iwatani, Y. and Akamizu, T.(2005):** Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. *J Clin Endocrinol Metab*. 90 (5):2898-903.

- Hiromatsu, Y.; Fukutani, T.; Ichimura, M.; Mukai, T.; Kaku, H.; Nakayama, H.; Miyake, I.; Shoji, S.; Koda, Y. and Bednarczuk, T. (2005)** Interleukin-13 Gene Polymorphisms Confer the Susceptibility of Japanese Populations to Graves' Disease The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 1 296-301.
- Hoffmann, P.; Eder, R.; Kunz-Schughart, L.A.; Andreesen, R. and Edinger, M. (2004):** Large-scale *in vitro* expansion of polyclonal human CD4 (+) CD25high regulatory T cells. Blood. **104**:895–903.
- Holm, H.; Coombes, J.; Mottet, C.; Izcue, A.; Thompson, C.; Fanger, A.; Tannapfel, A.; Fontenot, D.; Ramsdell, F. and Powrie, F. (2006):** Characterization of Foxp3⁺CD4⁺CD25⁺ and IL-10-Secreting CD4⁺CD25⁺ T Cells during Cure of Colitis. The Journal of Immunology.177: 5852-60.
- Hong , J.; Zang , Y. C. ; Nie, H. and Zhang , J. Z. (2006):** CD4⁺ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. PNAS. 103 (13) 5024-29.
- Hori, S.; Nomura, T. and Sakaguchi, S.(2003):** Control of regulatory T cell development by the transcription factor. Foxp3. Science, **299**, 1057–61.
- Huehn, J.; Siegmund, K. and Lehmann, J. (2004):** Developmental stage, phenotype and migration distinguish naive- and effector/memory-like CD4⁺ regulatory T cells. J Exp Med.;199: 303-13.
- Iagaru, A. and McDougall, I. R. (2007):** Treatment of Thyrotoxicosis. JNM 48: 379-89.

- Isotalo, P.A. and Lloyd, R.V.(2000):** p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. *Mod Pathol.*;13(9):1014-9.
- Itoh, M.; Uchimura, K.; Yamamoto, K.; Makino, M.; Imamura, S.; Kobayashi, T.; Fujiwara, K.; Kato, T.; Hayakawa, N.; Sawai, Y.; Nagasaka, A.; Iwase, K.; Nomura, T. and Hagino, Y. (2002):** Distinctive response of thyroid-infiltrating mononuclear cells to B cell activation through CD40 and interleukin-4 in Graves' patients. *Cytokine* 19(3):107-14.
- Jacobson, D.L.; Gange, S.J.; Rose, N.R. and Graham, N.M.(1997):** Epidemiology and estimated population burden of selected autoimmune diseases in the United States. *Clin Immunol Immunopathol*;84:223-243.
- Jansen, J.; Friesema, E.C.; Milici, C. and Visser, T.J. (2005):** Thyroid hormone transporters in health and disease. *Thyroid* 15;757-768.
- Jenkins, R.C. and Weetman, A. P. (2002):** Disease associations with autoimmune thyroid disease. *Thyroid*. 12(11):977-88.
- John, C. R. and Maurizio, P. (2005):** "Apoptosis-based therapies for hematological malignancies", *Blood*. 106(2):408-18.
- Jonathan, S. and Charles, D. S. (2003) :** Knowing one's self: central tolerance. *Nature Immunology* 4: 303 – 4.
- Jones, B.M.; Kwok, C.C. and Kung, A.W. (1999):** Effect of radioactive iodine therapy on cytokine production in Graves' diseases: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor- α with longer term increases

in interferon- γ production. Journal of Clinical Endocrinology and Metabolism, **84**, 4106–10.

Jonuleit, H.; Schmitt, E. and Stassen, M. (2001): Identification and functional characterization of human CD4(+) CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 193: 128594.

Jonuleit, H.; Schmitt, E.; Kakirman, H.; Stassen, M.; Knop, J. and Enk, A.H. (2002): Infectious tolerance: human CD25⁺ regulatory T cells convey suppressor activity to conventional CD4⁺ T helper cells. J Exp Med 196:255–60. |

Jonuleit, H. and Schmitt, E. (2003): The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 171:6323–7.

Kalinyak, J. E. and McDougall, I. R. (2003): How Should the Dose of Iodine-131 Be Determined in the Treatment of Graves' Hyperthyroidism? J. Clin. Endocrinol. Metab., March 1, 88(3): 975 - 77.

Kallmann, B.A.; Hüther, M.; Tubes, M.; Feldkamp, J.; Bertrams, J.; Gries, F.A.; Lampeter, E.F. and Kolb, H. (1997): Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes, **46**,237–43.

Kamizono, S.; Hiromatsu, Y.; Seki, N.; Bednarczuk, T.; Matsumoto, H.; Kimura, A. and Itoh, K. (2000): A polymorphism of the 5' flanking region of tumour necrosis factor α gene is associated with thyroid-associated ophthalmopathy in Japanese. Clin Endocrinol (Oxf) 52:759– 64

- Kenneth, R. S, and Julie, W. G. (2007):** Flow Cytometry and Immunospeak. Immunology/Microbiology for ID. Infectious Diseases in Clinical Practice. 15(3):183-91.
- Kobayashi, C.; Sasaki, H.; Kosuge, K.; Miyakita, Y.; Hayakawa, M.; Suzuki, A.; Abe, E.; Suzuki, K.; Aizawa, Y. (2005):** Severe starvation hypoglycemia and congestive heart failure induced by thyroid crisis, with accidentally induced severe liver dysfunction and disseminated intravascular coagulation. Intern Med. 44(3):234-9.
- Komiya, E.; Yamada, T.; Sato, A.; Kouki, T.; Nishimori, T. and Takasu, N. (2001):** Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin-13. Journal of Clinical Endocrinology and Metabolism, **86**,3540–44.
- Kouki, T.; Sawai, Y.; Gardine, C.; Fisfalen, M. E.; Alegre, M.L. and DeGroot, L. J . (2000):** CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 165:6606–11.
- Kung, A.W.; Lau, K. S. and Kohn, L.D. (2001):** Epitope mapping of TSH Receptor-blocking antibodies in Graves' disease that appear during pregnancy. J Clin Endocrinol Metab; **86**:3647-53.
- Landay, A. L. and Muirhead, K. A. (1989):** Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol. 52:48-60.

- Larsen, P.R.; Davies, T.F. and Hay, I.D.(1998):** The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams textbook of endocrinology. 9th ed. Philadelphia: W. B. Saunders Co.; 389–515.
- Latrofa, F.; Chazenbalk, G. D.; Pichurin, P.; Chen, C.-R.; McLachlan, S. M. and Rapoport, B. (2004):** Affinity-Enrichment of Thyrotropin Receptor Autoantibodies from Graves' Patients and Normal Individuals Provides Insight into Their Properties and Possible Origin from Natural Antibodies. J. Clin. Endocrinol. Metab. 89(9): 4734 - 45.
- Lehmann, J.; Huehn, J. and de la Rosa, M. (2002):** Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc Natl Acad Sci U S A.;99: 13031-36.
- Li, P.; Nijhawan, D. and Wang, X.(2004):**"Mitochondrial Activation of Apoptosis". Cell 116: 57-59.
- Li , B.; Saouaf , S.; Samanta , A.; Shen , Y.; Hancock , W. and Greene, M. (2007):** Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol. 17 : 17703930.
- Liao, L.; Long, G.; Liu, F.; Hu, H.; Li, G. and Feng, N. (2006):** Graves' disease. HKMJ. 12 (6): 79.
- Ling, E. M.; Smith, T and Nguyen, X.D. (2004):** Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet; 363: 60815.

- Liu, H. and Leung, B.P. (2006):** CD4⁺CD25⁺ regulatory T cells in health and disease .Clinical and Experimental Pharmacology and Physiology, Volume 33:519-24.
- Longhi, M. S.; Hussain, M. J.; Ragai, R. M.; Arora, S. K.; Vergani, Diego Vergani, G. M. and Ma, Y. (2006):** Functional Study of CD4⁺CD25⁺ Regulatory T Cells in Health and Autoimmune Hepatitis. The Journal of Immunology, 176: 4484-91.
- Lopez, E.R.; Zwermann, O.; Segni, M.; Meyer, G.; Reincke, M.; Seissler, J.; Herwig, J.; Usade,l K.H. and Badenhoop, K.(2004):** A promoter polymorphism of the CYP27B1 gene is associated with diabetes mellitus in Addison's disease, Hashimoto's thyroiditis, Graves' disease and type 1 Germans. Eur J Endocrinol. 151(2):193-7.
- MacDonald, A. J.; Duffy, M. and Brady, M.T .(2002):** CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis . 185: 7207.
- Maloy, K.J. and Powrie, F.(2001):** Regulatory T cells in the control of immune pathology. Nat Immunol.;2:816–22.
- Marians, R.C.; Ng, L.; Blair, H.C.; Unger, P.; Graves, P.N. and Davies, T.F. (2002):** Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proceedings of the National Academy of Sciences of the United States of America; 99:15776-81.

- Marino, M.; Ricciardi, R.; Pinchera, A.; Barbesino, G.; Manetti, L.; Chiovato, L.; Braverman, L.E.; Rossi, B.; Muratorio, A. and Mariotti, S.(1997):** Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. *J Clin Endocrinol Metab* 82:438-43.
- Marino, M.; Chiovato, L.; Friedlander, J.A.; Latrofa, F.; Pinchera, A. and McCluskey, R.T.(1999):** Serum antibodies against megalin (GP330) in patients with autoimmune thyroiditis. *J Clin Endocrinol Metab.* 84:2468-74.
- Marino, M.; Zheng, G.; Chiovato, L.; Pinchera, A.; Brown, D.; Andrews, D. and McCluskey, R.T.(2000):** Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells: a novel function in the control of thyroid hormone release. *J. Biol. Chem.* 275: 7125-38.
- Mariotti, S.; Pisani, S.; Russova, A. and Pinchera, A.(1982):** A new solidphase immunoradiometric assay for anti-thyroglobulin antibody. *J Endocrinol Invest*; 5: 227-33.
- Mariotti, S. and Pinchera, A.(1990):** The thyroid gland. In Greer MA Ed.. Raven Press Ltd, New York: 147-52
- Mariotti, S.; Caturegli, P.; Piccolo, P. and Barbesino, G, P. (1990):** Anti thyroid peroxidase antibodies in thyroid diseases. *J Clin Edocrinol Metab.*; 71: 661-69.
- Mariotti, S.; Barbesino, G. and Caturegli, P. (1995):** Assay of thyroglobulin in serum with thyroglobulin antibodies: an unobtainable goal? *J Clin Endocirol Metab*; 80: 468-72.
- Marti, G.E.; Stetler-Stevenson, M.; Bleesing, J.J. and Fleisher, T.A. (2001):** Introduction to Flow Cytometry. *Sem Hematology* 38(2): 93-9.

- Matos-Santos, A.; Nobre, E.L.; Costa, J.G.; Nogueira, P.J.; Macedo, A.; Galvao-Teles, A. and de Castro, J.J. (2001):** Relationship between the number and impact of stressful life events and the onset of Graves' disease and toxic nodular goiter. *Clin Endocrinol* 55:15-19.
- Matsuura, N.; Yamada, Y.; Nohara, Y.; Konishi, J.; Kasagi, K.; Endo, K.; Kojima, K. and Wataya, K. (1980):** Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunoglobulins. *N Engl J Med* 303:738–41.
- McGee , H.S. (2006):** Foxp3 Tr1 Regulatory T cells as a Therapeutic Antidote in Reversing Cockroach-Induced Asthma **Journal of Allergy and Clinical Immunology** 117(2) :241.
- McLachlan, S. M. and Rapoport, B.(1992):** The molecular biology of thyroid peroxidase: Cloning, expression, and role as autoantigen in autoimmune thyroid disease. *Endocrine Rev*; 13:192-206.
- McLachlan, S.M. and Rapoport, B. (1996):** Monoclonal, human autoantibodies to the TSH receptor -- the Holy Grail and why are we looking for it? *J Clin Endocrinol Metab*;81:3152-54.
- Metso, S. (2004):** Long-term follow-up study of radioiodine treatment of hyperthyroidism. *Clin Endocrinol (Oxf)* 61: 641–48.
- Mihara, S.; Suzuki, N.; Wakisaka, S.; Suzuki, S.; Sekita, N.; Yamamoto, S.; Saito, N.; Hoshino, T. and Sakane, T. (1999):** Effects of Thyroid Hormones on Apoptotic Cell Death of Human Lymphocytes. *J. Clin. Endocrinol. Metab.* 84(4): 1378 - 85.